Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875609 · ClinicalTrials.gov registry record
ctDNA in Cutaneous Squamous Cell Carcinoma
A clinical trial of Cutaneous Squamous Cell Carcinoma, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06875609: Recruiting study of Cutaneous Squamous Cell Carcinoma, sponsored by Massachusetts Eye and Ear Infirmary.
NCT06875609 is a study of Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 60 participants, below the 89-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06875609, a study of Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Primary Outcome
To determine if there is an association between ctDNA clearance (defined as no detection of ctDNA) after surgical intervention and 2-year recurrence-free survival (RFS). The outcome will measure both ctDNA clearance (as a binary variable: detection or no detection) and RFS (measured in months). The association between these two outcomes will be analyzed as the primary outcome to determine if no detection of ctDNA is associated with longer RFS.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood and Tissue Collection
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2029-04-30 |
What NCT06875609 shows while recruiting
NCT06875609 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 89-participant average among 18 other Cutaneous Squamous Cell Carcinoma trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Cutaneous Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood and Tissue Collection is the first listed.
NCT06875609 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06875609 about?
NCT06875609 is a clinical study titled "ctDNA in Cutaneous Squamous Cell Carcinoma". The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
What is the current status of trial NCT06875609?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-03-24. Estimated completion is 2029-04-30.
What conditions does trial NCT06875609 study?
This clinical trial studies the following conditions: Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06875609?
The interventions under investigation include: Blood and Tissue Collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06875609?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875609 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06875609's enrollment target sits among peer trials
60 8th of 18 higher than 11 of 18 other Cutaneous Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI